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Antiphospholipids in hemodialysis patients: Relationship between lu.
pus anticoagulant and thrombosis. Vascular access thrombosis (VAT) is
frequent in some hemodialysis patients. Antiphospholipid antibodies(APL) have been involved in thrombosis, and have been reported to be
present in a high proportion of patients with chronic renal failure. We
studied the relationship between APL and thrombosis in 97 hcmodialysis
patients (HD). Lupus anticoagulant (LA) was assessed by activated partial
thromboplastin time (APT) and by tissue thromboplastin inhibition
assay (iTI). IgG-anticardiolipin (ACA) was measured by a solid phase
ELISA. The prevalence of APLwas 31%; LA was found in 16.5% and was
detected in all cases by ff1. Only one patient was positive for APTT. ACA
was found in 15.5%. Only one patient was positive for LA and ACA. We
found no relation between APL and age, length of time on dialysis, sex,
type of dialysis membrane, drugs, and chronic B and C hepatitis. A high
prevalence of APL was found in patients with undetermined nephropathy.
When histories of thrombosis were examined, VAT was found to be
significantly more frequent in patients with LA than in patients without
LA (62% vs. 26%; P = 0.01). This relation was not present with ACA.
Since VAT is one of the most frequent causes of morbidity for HD,
diagnostic evaluation of VAT in HD should now include assay for LA.
Lupus anticoagulant (LA) and anticardiolipin antibodies
(ACA) are acquired antiphospholipid antibodies (APL) which
may be present in a variety of conditions. Classically, they are
found in patients with systemic lupus erythematosus (SLE) or
related autoimmune disorders, but they may also be detected in
acute or chronic infections, neoplasia, and with certain drugs such
as phenytoin, hydralazine, isoniazid, procainamide, penicillin,
methyldopa and phenothiazines. Some individuals, however, have
no identifiable underlying disorder and may be regarded as having
primary antiphospholipid syndrome. The clinical manifestations
linked with APL most notably involved thrombosis, recurrent fetal
loss and thrombocytopenia which are present in about 30% of the
cases; they also involved less reported conditions such as livedo
reticularis, leg ulcers, epilepsy, chorea, pulmonary hypertension,
positive direct Coombs' test [1—6]. In addition, renal involvement
with hypertension, proteinuria and renal failure has been reported
in association with APL [7—9].
The study of APL in hemodialysis patients is justified by the
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frequency of vascular access thrombosis in this population where
thrombosis risk factors must be identified. A higher frequency of
elevated APL antibodies has been found in patients with end-
stage renal disease (ESRD) compared to the general population
[10, 11]. Moreover, the prevalence of APL is higher among
patients treated by hemodialysis than in ESRD patients on
conservative treatment [12] or on CAPD [13]. According to the
report of Quereda [12], the prevalence of LA was 11% in ESRD
patients on conservative treatment and 30% in patients treated
with hemodialysis. The higher rate in hemodialysis patients was
confirmed by others [10]. The mechanism of increase in APL in
these patients is unknown. Garcia-Martin et at found that patients
dialyzed with cuprophane membranes had a greater incidence of
ACA than patients treated with more biocompatible membranes
[10]. They suggested that membrane biocompatibility plays a role
in the occurrence of APL antibodies. Reports on the clinical
relevance of APL in hemodialysis (HD) patients are discordant
[10, 12—14], but some studies have suggested that APL antibodies
are involved in thrombotic complications of hemodialysis patients
[15, 16].
Many reports have shown differences between LA and ACA [6,
17—20]. Fractions of immunoglobulin with LA activity have been
separated from fractions with cardiolipin binding activity [17].
Purified ACA does not have LA activity in coagulation assays in
vitro [18]. ACA and LA appear to be directed against different
combinations of phospholipid moities and complexes: LA inter-
acts principally with phospholipids in a hexagonal conformation,
whereas ACA has an affinity for lamellar conformation [6, 19]; LA
can interact with multiple negatively charged phospholipids, and
principally with phosphatidylserine [20]. It has been reported that
clinical syndromes associated with LA and ACA are distinct [3, 6,
21], LA being more commonly associated with venous thrombosis
than with arterial thrombosis [6].
We performed a cross sectional study of APL antibodies in 97
stable ESRD patients treated with hemodialysis. At the same
time, as APL are acquired antibodies, we analyzed factors which
could be associated with APL. Then we attempted to retrospec-
tively evaluate the clinical influence of APL antibodies on throm-
bosis and analyzed the histories of thrombotic complications. For
the first time, a significant relation between LA and thrombosis is
shown in hemodialysis patients. Finally, some data concerning the
outcome of patients with APL antibodies after a two year
follow-up are included.
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Table 1A. Prevalence of antiphospholipids, lupus anticoagulants and




positive negative 95%(N — 30) (N 67) Odds Confidence P
N(%) ratio interval value
< 50 5 (16.7) 22(32.8) 0.41 0.11—1.31 0.16
50—69 16 (53.3) 28(41.8) 1.59 0.61—4.14 0.40





positive negative(N = 16) (N = 81) Odds Confidence P
N (%) ratio interval value
< 50 3 (19) 24(30) 0.55 0.09—2.27 0.54
50—69 8 (50) 36(44) 1.25 0.38—4.13 0.89




positive negative 95%(N = 15) (N= 82) Odds Confidence P
N (%) ratio interval value
< 50 2(13) 25 (30) 0.35 0.04—1.75 0.22
50—69 9(60) 35 (43) 2.01 0.57—7.51 0.39
> 70 4 (27) 22 (27) 0.99 0.21—3.82 1
Table lB. Prevalence of antiphospholipids, lupus anticoagulants and
anticardiolipins according to sex
Antiphospholipid Antiphospholipid
positive negative 95%(N=30) (N=67)
—____________________________ Odds Confidence P
N (%) ratio interval valueSex
Female 8 (26.7) 31(46.3) 0.42 0.15—1.18 0.11
Male 22(73.3) 36(53.7) 2.37 0.85—6.78 0.11
Lupus Lupus
anticoagulant anticoagulant
positive negative(N = 16) (N = 81) Odds Confidence P
N (%) ratio interval valueSex
Female 3 (19) 36 (44) 0.29 0.05—1.18 0.10
Male 13 (81) 45 (56) 3.47 0.85—20.17 0.10
Anticardiolipin Anticardiolipin
positive negative(N = 15) (N = 82) Odds Confidence P
N (%) ratio interval value
5 (33) 34 (41) 0.71 0.17—2.53 0.76
Sex
Female
Male 10(67) 48 (59) 1.42 0.40—5.76 0.76
Methods
Patients
All patients treated in our hospital-dialysis unit were initially
selected. Patients were excluded: if they were receiving drugs
known to induce APL (phenytoin, hydralazine, isoniazid, procain-
amide, penicillin, methyldopa and phenothiazines); if they were
treated with heparin, which interferes with LA test; if they were
diagnosed with SLE; if they had had acute infection or thrombosis
Table 1C. Prevalence of antiphospholipids, lupus anticoagulants and






positive negative(N = 30) (N = 67) Odds Confidence
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in the previous month; or if they declined to give their consent to
participate in the study.
Ninety-seven patients treated by regular hemodialysis were
evaluated: 58 male, 39 female; aged 58.7 15.8 years (mean
SD); time on dialysis 83.4 75.3 months. Initial nephropathies
were: glomerulonephritis (31), interstitial nephritis (13), neph-
roangiosclerosis (11), polycystic kidneys (8), diabetes (7), amy-
loidosis (3), cortical necrosis (2), congenital (2), vascular (1), or
undetermined (19). Dialysis treatment was performed with bicar-
bonate buffer and hollow-fiber dialyzers with cellulosic acetate
membranes (71), polysulfone (16) and polyacrylonitrile (10).
Anticoagulation during dialysis was performed with heparin,
which was administered in a constant infusion at a dose of 30 U/kg
during the first hour and 500 to 1000 U/hr thereafter.
Hemodialysis vascular access was a native arteriovenous fistula
in 79 cases, a graft fistula in 15 cases (polytetrafluoroethylene 10;
bovine carotid 2; autogenous saphene 3), and a PermCath (Quin-
ton, Seattle, WA, USA) in 3 cases. Graft fistulas or catheters were
used only after one or many failures of native arteriovenous
fistulas.
Blood was obtained from the hemodialysis vascular access,
before the beginning of the session. The study was performed
between June and December 1992.
Laboratoiy procedures
Lupus anticoagulant was assessed on blood samples collected
into a citrate anticoagulant with antiplatelet mixture solution.
Platelet-poor plasma was obtained by two successive centrifuga-
tions of 10 minutes at 2500 g at room temperature. Then plasma
was frozen at —70°C. The procedure combined two phospholipid-
dependent assays. Positivity was determined as recommended by
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the Working Group on Hemostasis of the Société Française de
Biologie Clinique [22].
Activated partial thromboplastin time (APTT) was measured
using the automated APTT reagent (Organon-Teknika). Mixing
studies were carried out on 1:1 mixtures (one part of patient
plasma and one part of a normal plasma pool) without incubation.
Results were expressed using a numerical index as described by
Rosner et al [23], calculated according to the formula: [(A —
B):CI x 100, where A is the clotting time of the mixture, B the
time of the normal plasma and C the time of the patient's plasma.
An APTT index of 1.5 or greater was considered as positive.
Tissue thromboplastin inhibition assay (Tn) was performed
using a 1:100 and a 1:500 dilution of the thromboplastin reagent
(Neoplastin, Diagnostica Stago). The test was run as a single
reagent system with the prothrombin time mode, that is, 0.2 ml
diluted thromboplastin added to 0.1 ml of plasma. Mixing studies
were carried out on a 1:1 mixture without incubation. Results
were expressed as the ratio of the clotting time of the mixture to
that of the normal plasma. A ITI index of 1.2 or greater was
defined as positive.
A plasma was said to be positive for LA if it gave a positive
result with at least one assay. To improve specificity and clinical
relevance, results in the borderline range were considered to be
negative.
IgG-anticardiolipin antibodies were determined in serum by a
solid phase enzyme-linked immunosorbent assay performed in
accordance with the recommendations of the workshop on stan-
dardization of anticardiolipin assays [24]. Results are expressed in
IgG phospholipid (GPL) units. The value of each serum was
determined from a log-log standard curve constructed using six
standard samples comprised of six dilutions of a positive serum
pooi from 1:100 to 1:6,400. The value of each dilution had
previously been determined using nine standard samples supplied
by Dr. Harris (Louisville, KY, USA). Normal values were estab-
lished by studying 100 clinically healthy individuals. Values higher
than 20 GPL U (mean of 100 normal sera 3 SD) were considered
to be positive.
Serum globulin levels were assessed every six months by serum
electrophoresis on cellulose acetate gel (Cellogel) at pH 8.6 with
a Sebia EPU analyzer.
Clinical data
Histories of thrombosis were reviewed from patient medical
records completed with direct questioning. Only thrombotic
events with complete vascular occlusion were recorded. The
following were excluded: angina pectoris, peripheral arteriopathy,
or insufficiency of arterio-venous fistula. No time limit was set for
review of patient medical histories. Thrombotic events occurring
before or after initiating chronic dialysis treatment were distin-
guished. Blood pressure (BP) was evaluated from measurements
conducted before the dialysis session. Patients were classified
according to systolic BP into two groups: (1) BP inferior to 120
mm Hg (N = 16); (2) BP superior or equal to 120 mm Hg (N =
81).
Statistical analysis
Data are expressed as mean SD. Patients with and without
APL (LA and/or ACA) were analyzed. The prevalence of factors
suspected of being associated with APL occurrence, and preva-
lence of histories of thrombotic complications associated with
these antibodies were studied, Groups were compared using the
chi-square test with Yates's correction or Fisher's exact test, with
odds ratios and 95% confidence intervals of odds ratio.
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interval P valueN (%)
Glomerular 5 (16.7) 26 (38.8) 0.32 0.08—1.00 0.05
Interstitial 5 (16.7) 8 (11.9) 1.48 0.34—5.70 0.53
Nephrosclerosis 3 (10) 8 (11.9) 0.82 0.13—3.77 1
Vascular 1(3.3) 0 md md 0.31
Polycystic 3 (10) 5 (7.5) 1.38 0.20—7.65 0.70
Diabetic 2 (6.7) 5 (7.5) 0.89 0.08 —5.83 1
Hereditary 0 2(3) 0.00 0.00—11.96 1
Amyloid 0 3 (4.5) 0.00 0.00—5.43 0.55
Cortical necrosis 0 2 (3) 0.00 0.00—11.96 1
Undetermined 11(36.7) 8(11.9) 4.27 1.34—13.88 0.01
Table 3. Prevalence of antiphospholipids according to treatment
Antiphospholipid Antiphospholipid
Treatment
positive(N=30) negative(N=67) 95%Odds Confidence P
(drug) N (%) ratio interval value
Aspirin 3 (10) 8 (12) 0.82 0.13—3.77 1
Beta 2(7) 4(6) 1.13 0.10—8.37 1
blockers
ACE! 2 (7) 7 (10) 0.61 0.06—3.52 0.72
Calcium 5(17) 14(21) 0.76 0.19—2.56 0.83
inhibitors
Prazosine 0 1(1) 0.00 0.00—87.1 1
Guafancine 0 1(1) 0.00 0.00—87.1 1
Clonidine 0 1(1) 0.00 0.00—87.1 1
Furosemide 4(13) 3(4) 3.28 0.51—23.650.20
Results
The prevalence of antiphospholipid antibodies in our popula-
tion was 31% (30 of 97). Patients with LA represented 16.5% (16
of 97) and patients with ACA 15.5% (15 of 97). Only one patient
had the two antibodies. LA were detected in all cases by TEl. Only
one patient was positive for TI! and APTI'. Anticardiolipin
values were considered to be positive when they were superior to
20 U. Among the 15 positive patients, 12 had values between 20
and 50, 1 between 51 and 100 and 2 superior to 100.
Factors which have been associated with APL in other reports
were analyzed (Table 1). No relation was found between APL and
age. The proportion of males was higher in patients with APL, but
not significantly. No relation was found between APL frequency
and the length of time on hemodialysis, or the type of dialysis
membrane. When the influence of initial nephropathy was exam-
ined (Table 2), the prevalence of APL was low in patients with
chronic glomerulonephritis. The highest prevalence was found in
patients with undetermined nephropathy. Patients receiving drugs
linked with the presence of antiphospholipid were excluded. On
the contrary, other drugs such as aspirin have been reported to
decrease APL. There was no influence of aspirin treatment on
either AL or ACA prevalence (Table 3), and no influence of
antihypertensive medications was found on APL prevalence.
There was no assocation between APL and hypergammaglobu-
linemia or thrombopenia. Antinuclear AB and anti-DNA AB
were assessed in 23 patients with APL. Antinuclear AB were
present in 7 of 23 cases: 4 of 14 patients with LA and 3 of 9
Table 4. Prevalence of antiphospholipids according to chronic hepatitis
C and B infections
Antiphospholipid Antiphospholipid









C Hepatitis 6(20) 20(30) 0.59 0.17—1.79 0.44
positive
B Hepatitis 4(13) 6(9) 1.56 0.30—7.21 0.49
positive
patients with ACA, Anti-DNA AB were absent in all cases. No
relation was found between APL and chronic B and C hepatitis
virus infections (Table 4). No patient was infected by human
immunodeficiency virus.
Then the clinical influence of antiphospholipid antibodies on
thrombosis was retrospectively evaluated. Histories of thrombosis
were found in 41 patients: arterial thrombosis was reported in 17
patients, venous thrombosis in 7, and hemodialysis vascular access
in 3l. Among arterial and venous thrombosis events, 46% oc-
curred before and 54% after initiating chronic dialysis treatment.
The presence of APL (ACA and/or LA) was found in 39% (16 of
41) of the patients with history of thrombosis. LA was present in
27% (11 of 41), and ACA was present in 12% (5 of 41).
In addition, we looked at the frequency of thrombotic events in
patients with APL (Table 5). Globally, history of thrombosis was
noted in 53% of patients with APL and in 37% of patients
without. This difference was not significant. When we separately
considered the respective influence of LA and ACA, we noted
that thrombosis was more frequent in patients with LA (69%)
than in those without (37%). This finding was due to the
relationship between LA and histories of vascular access throm-
bosis, which were significantly more frequent in patients with LA
than in those without (62% vs. 26%; P = 0.010). This relation was
not present with ACA. The highest values of ACA were not
associated with thrombosis: among the three patients with ACA
superior to 50 U, only one experienced thrombotic events.
As the study was performed in 1992, some information on the
outcome of patients is available. In January 1995 we analyzed the
proportion of deaths and renal transplantations (Table 6); we also
performed a new measurement of APL for 8 ACA-positive and 11
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Table 5. Histories of thrombosis according to the presence or absence












All sites 16 (53) 25 (37) 1.92 0.74—5.03 0.21
Arterial 7 (23) 10 (15) 1.73 0.52—5.76 0.47
Venous 1(3) 6 (9) 0.35 0.01—3.13 0.30











All Sites 11(69) 30 (37) 3.74 1.06—14.9 0.038
Arterial 2(12) 15 (18) 0.63 0.06—3.24 0.73
Venous 1(6) 6 (7) 0.83 0.02—7.71 1










All sites 5 (33) 36 (44) 0.64 0.16—2.29 0.63
Arterial 5 (33) 12(15) 2.92 0.66—11.42 0.13
Venous 0 7 (9) 0 0—3.89 0.59
Vascular 3 (20) 28 (34) 0.48 0.08—2.01 0.37
access
LA-positive patients still treated with HD. Among the 8 ACA-
positive patients not one was positive, and among the 11 LA-
positive patients 7 (64%) remained positive two years later.
Discussion
There was a prevalence of 31% for APL antibodies in our
hemodialysis population. In the literature, the prevalence of APL
in dialysis patients is quite variable: 37% for Garcia-Martin et al
[10], 13% for Chew et al [14] and 4.8% for Phillips et al [25]. The
respective prevalence of LA and ACA among these groups is also
variable: 16.5% and 15.5% in our population, 22% and 31% for
Garcia-Martin et al, 5.5% and 9% for Chew et al, 0% and 4.8%
for Phillips et al. The mechanism of this variability is unknown.
Drugs, infections, genetics and lipid intake have been suggested as
contributing factors [25]. It could also be due to the different
methods of measurement used. In our study, all LA were detected
by iTT method and only one by APTF. The laboratory methods
used to assess APL antibodies are debated [26, 27]. It is recog-
nized that the different reagents used in APTT tests vary signifi-
cantly in their LA sensitivity. On the other hand, it has been
recently suggested that 'TTI could be one of the most sensitive
tests for LA [27].
The mechanism of increase in APL in hemodialysis patients is
unknown. The search for factors involved in APL occurrence in
our patients showed no relation between APL and age or sex. The
relations described in the literature between APL and hypergam-
maglobulinemia [28] or anti-DNA AB [29] were not found in this
Table 6. Outcome of patients according to the presence or absence of








Death 4 (25) 17 (21) 1.25 0.26—4.86 0.74
Transplantation 0 8 (10) 0 0—2.99 0.35
Outcome
Anticardiolipin Anticardiolipin




Death 5 (33) 16 (20) 2.06 0.48—7.76 0.30
Transplantation 2 (13) 6 (7) 1.95 0.17—12.46 0.61
study. A high prevalence of APL has been reported in patients
with end-stage renal disease on conservative treatment [10, 12],
and hence chronic renal failure per se may account for the rise in
APL. Although APL has been reported as being more common
among patients with chronic glomerulonephritis [11], these ne-
phropathies were not associated with APL in our patients. The
highest prevalence was found in the undetermined nephropathy
group (Table 2). It must be emphasized that patients with
antinuclear antibodies were not more frequent in this group than
in others (29% vs. 31%). Renal involvement has been reported in
association with APL antibodies [7—9], but no patient in this group
met the criteria for APL syndrome. Patients receiving drugs
known to induce APL were excluded from this study. No associ-
ation was found between APL and other drugs such as antihyper-
tensive, calcium carbonate and vitamin D. APL have been asso-
ciated with hemodialysis on Cuprophan membranes, which lead to
bioincompatibility reactions with patient blood [10]. There was no
relation between APL and type of dialysis membrane in our
patients, but we did not use Cuprophan membranes. On the other
hand, APL are frequently seen as a reaction to infections, and
these antibodies may arise as a response to foreign antigens
present in bacteria [30] such as endotoxins which contain phos-
phate groups with similar distribution to cardiolipin. Hemodialysis
patients are regularly exposed to endotoxins present in the
dialysate. This repeated contact between blood and dialysate may
account for the occurrence of APL. However, this hypothesis
cannot explain the lack of correlation between APL and length of
time on hemodialysis and the fact that APL were not present in
every hemodialysis patient exposed to the same dialysate.
The study was performed in 1992. When the outcome of
patients after two years was evaluated (Table 6), mortality was not
different when LA- or ACA-positive patients were compared with
negative patients. The same proportion of patients were trans-
planted in the different groups. Moreover, a new test was per-
formed for some patients still treated by HD in 1995. Among 8
patients with initially positive ACA, not one was positive; among
11 patients with initially positive LA, 7 (64%) were positive. These
results confirm that APL levels can change over time [31]. In our
study ACA varied widely. This may be due to the low initial levels
of these antibodies in our population and to some variation in test
sensitivity. LA varied only slightly in these HD patients.
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In this study, some evidence is provided to confirm that LA and
ACA are separate entities, as suggested by other reports [3, 6,
17—21]. Contrary to LA, ACA antibodies were not associated with
an increased risk of thrombosis. The lack of concordance between
the results of LA tests and ACA tests in our patients is important.
LA and ACA were simultaneously found in only one patient.
Classically, LA and ACA correlation is 30% in SLE. However, it
is now recognized that most of the time in non-SLE disorders one
antibody occurs without the other being present [6].
The primary result of this study is the higher number of patients
with a history of vascular access thrombosis in the LA-positive
group than in LA-negative group (62% vs. 26%, odds ratio =
4.76). Because this study is retrospective, a causal relation be-
tween LA and the risk of vascular access thrombosis should be
inferred with caution. It is unknown if APL was actually present at
the time of thrombosis. However, virtually all the studies that have
been done have related the results of current antibody tests to
previous thrombotic events [21]. A prospective study on the
clinical relevance of APL is not possible in our population, since
among the 16 patients with LA, 10 are currently being treated with
an oral anticoagulant. An association between APL and a history
of arterial or venous thrombosis is well-known in patients with
SLE or non-SLE disorders, in which thrombotic events occurred
respectively in 42% and 22% of patients with LA. In hemodialysis
patients, Quereda et al [12] reported histories of thrombosis in
23% in patients with LA versus 13% in patients without, but this
difference was not significant. Our results show, for the first time,
a significant relation between LA and vascular access thrombosis
in these patients. It is surprising that lupus anticoagulant was
associated only with vascular access thrombotic events and not
with arterial or venous thrombosis. However, hemodialysis pa-
tients are particularly exposed to vascular access thrombosis,
which in the majority of the cases is the result of outflow stenosis
secondary to intimal hyperplasia [32]. The presence of lupus
anticoagulant may lead to thrombosis on sites which are already
exposed to thrombosis risk. We cannot eliminate the influence of
other factors such as low systolic BP on thrombotic events.
However, low BP did not appear as a significant risk factor of
vascular access thrombosis in this study (odds ratio = 0.54).
These results may have practical implications since vascular
access thrombosis is one of the most frequent causes of hospital-
izations for dialysis patients [33]. Diagnostic evaluation of vascu-
lar access thrombosis in hemodialysis patients must now include
an assay for LA. On the other hand, LA assessment is not
recommended at present in all HD patients because some patients
with LA never had thrombotic complications. In the future, more
specific methods of identifying thrombotic forms of APL will be
useful. These methods should be based on an understanding of
the mechanisms of thrombosis in these patients: APL could
interact with endothelial cells and prostacyclin production [341,
with the thrombomodulin-protein C pathway [35], with prekal-
likrein activity [36], with antithrombin III [37] and with platelets
[38]. The clinical relevance of APL could also be due to the
presence of the APL-cofactor, /32-glycoprotein 1 [27, 39].
Although the preventive treatment of vascular access thrombo-
sis in hemodialysis patients is controversial [33], patients with a
history of thrombosis and presence of LA need to be on long-term
anticoagulant therapy. In patients with severe and recurrent
thrombotic complications, recommended treatment consists of
long-term subcutaneous low-molecular weight heparin or Couma-
din, plus in some cases, low-dose aspirin.
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